SGLT2 inhibition: A novel prospective strategy in treatment of diabetes mellitus

Renal Failure

Volumn 35, Issue 4, 2013, Pages 566-572

  Deshmukh, Aaishwarya B ^a   Patel, Maharshi C ^a   Mishra, Bharat ^b  

^a Shankersinh Vaghela Bapu Institute of Pharmacy   (India)

^b NOOTAN PHARMACY COLLEGE   (India)

Author keywords

Hyperglycemia; Kidney; Sodium glucose co transport; Sodium glucose co transporter 2 (SGLT2) inhibitors; Type 2 diabetes

Indexed keywords

3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ANTIDIABETIC AGENT; DAPAGLIFLOZIN; GLUCOSE; INSULIN; METFORMIN; PHLORIZIN; PLACEBO; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

CELL FUNCTION; COMPETITIVE INHIBITION; DIABETIC PATIENT; DIET RESTRICTION; DOSE RESPONSE; GLOMERULUS FILTRATION; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY TUBULE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE DRUG DOSE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; OBESITY; PROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84876376082     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.766560     Document Type: Review

References (60)

1. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic costs of non-insulin-dependent diabetes mellitus. J Am Med Assoc. 1989;262:2708-2713
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-1431
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med. 1993;329: 977-986
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352:837-853
5. DeFronzo RA. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes. Diabetes Rev. 1997;5:177-269
6. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodiumglucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;4:515-531
7. Wing RR, Lang W, Wadden TA, et al. The look ARG: Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481-1486
8. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193-203
9. Blonde L. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve Clin J Med. 2009;76:S4-S11
10. Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: Rationale for rational use of insulin. Mayo Clin Proc. 2003;78:459-467
11. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32:S151-S156
12. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med. 2008;23:588-594
13. Dokken B. The kidney as a treatment target for type 2 diabetes. Diabetes Spectrum. 2012;25:29-36
14. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodiumglucose transport: Role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75:1272-1277
15. +)-glucose co transporters. Am J Physiol Renal Physiol. 2001;280:F10-F18
16. Hediger MA, Kanai Y, You G, Nussberger S. Mammalian ioncoupled solute transporters. J Physiol. 1995;482:7S-17S
17. Chin E, Zhou J, Bondy C. Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney. J Clin Invest. 1993;91:1810-1815
18. Ferrannini E. Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant. 2010;25:2041- 2043
19. Ferrannini E. Learning from glycosuria. Diabetes. 2011;60: 695-696
20. Valtin H. Tubular reabsorption. In: Schafer JA, James A, eds. Renal Function. Boston, MA: Little, Brown and Company; 1983
21. Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52:1147-1154
22. Norton L, DeFronzo RA, Muhammad AA. Sodium-glucose cotransporter 2 tnhibition - a novel strategy for glucose control in type 2 diabetes. US Endocrinology. 2010;6(1):42-47
23. +/glucose cotransporter. Nature. 1987;330:379-381
24. +/glucose cotransporter SGLT2: Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest. 1994;93:397-404
25. Diez-Sampedro A, Hirayama BA, Osswald C, et al. A glucose sensor hiding in a family of transporters. Proc Natl Acad Sci USA. 2003;100:11753-11758
26. Santer R, Calado J. Familial renal glucosuria and SGLT2: From a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5:133-141
27. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamics during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest. 2010;28:101-109
28. Chin E, Zamah AM, Landau D, et al. Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney. Endocrinology. 1997;138:1267-1275
29. Kamran M, Peterson RG, Dominguez JH. Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol. 1997;8:943-948
30. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with noninsulin-dependent diabetes. Diabetes. 2005;54:3427-3434
31. +)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: Involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology. 2008;149:717-724
32. Freitas HS, D'Agord SB, da Silva RS, Okamoto MM, Oliveira- Souza M, Machado UF. Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats. Nephron Physiol. 2007;105:42-51
33. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature. 1996;384:455-458
34. Pontoglio M, Sreenan S, Roe M, et al. Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest. 1998;101:2215-2222
35. Pontoglio M, Prie D, Cheret C, et al. HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000;1:359-365
36. Dominguez JH, Camp K, Maianu L, Feister H, Garvey WT. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol. 1994;266:F283-F290
37. Dominguez JH, Song B, Maianu L, Garvey WT, Qulali M. Gene expression of epithelial glucose transporters: The role of diabetes mellitus. J Am Soc Nephrol. 1994;5:S29-S36
38. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30:125-129
39. +/glucose cotransporter activity in renal proximal tubule cells. Am J Physiol Renal Physiol. 2004;288:F988-F996
40. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: Blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008;62:1279-1284
41. Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57:1723-1729
42. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest. 1991;87:561-570
43. Bailey CJ, Gross JL, Pieters A, Bastein A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, doubleblind, placebo-controlled trial. Lancet. 2010;375:2223-2233
44. Kipnes MS. Sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: A review of phase II and III trials. Clin Invest. 2010;1:145-156
45. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: Rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011;123:133-143
46. Misra M. SGLT2 inhibitors: A promising new therapeutic option for treatment of type 2 diabetes mellitus. J Pharm Pharmacol. 2013;65(3):317-327
47. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510-1515
48. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, FujikuraH, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008;327:268-276
49. Kennedy RL, Chokkalingam K, Farshchi HR. Nutrition in patients with type 2 diabetes: Are low-carbohydrate diets effective, safe or desirable? Diabet Med. 2005;22:821-832
50. Geerlings SE, Stolk RP, Camps MJ, et al. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care. 2000;23:1737-1741
51. Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: An emerging new class of oral antidiabetic drug. Diabetes Obes Metabol. 2009;11:79-88
52. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513-519
53. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodiumglucose co-transport inhibition with dapagliflozin in type 2 diabetes mellitus. Diabetes Care. 2009;32:650-657
54. +- glucose cotransporters, in streptozotocin-induced diabetic rats. Jpn J Pharmacol. 2000;84:351-354
55. Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320:323-330
56. Kolodny EH, Kline R, Altszuler N. Effect of phlorizin on hepatic glucose output. Am J Physiol. 1962;202:149-154
57. +)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol. 2000;391: 183-192
58. Leahy JL, Bonner-Weir S,Weir GC. Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy. J Clin Invest. 1988;81: 1407-1414
59. Olson LK, Redmon JB, Towle HC, Robertson RP. Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. J Clin Invest. 1993; 92:514-519
60. +-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol. 2002; 29:386-390